Review Article

Microbiome and Gestational Diabetes: Interactions with Pregnancy Outcome and Long-Term Infant Health

Caterina Neri,1 Erika Serafino,1 Maddalena Morlando,2 and Alessandra Familiari1

1Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy
2Prenatal Diagnosis and High Risk Pregnancy Unit, Department of Woman, Child and of General and Specialized Surgery, University "Luigi Vanvitelli", Naples, Italy

Correspondence should be addressed to Caterina Neri; caterina.neri@policlinicogemelli.it

Received 25 March 2021; Accepted 26 October 2021; Published 25 November 2021

Academic Editor: Christian S. Goebl

Copyright © 2021 Caterina Neri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Microbiota composition is progressively being connected to different physiologic effects, such as glucose metabolism, and also to different pathologies, such as gestational diabetes mellitus (GDM). GDM is a public health concern that affects an important percentage of pregnancies and is correlated with many adverse maternal and neonatal outcomes. An increasing number of studies are showing some connections between specific microbial composition of the gut microbiota and development of GDM and adverse outcomes in mothers and neonates. The aim of this review is to analyze the available data on microbial changes that characterize healthy pregnancies and pregnancies complicated by GDM and to understand the correlation of these changes with adverse maternal outcomes; this review will also discuss the consequences of these maternal gut microbiome alterations on neonatal microbiota composition and neonatal long-term outcomes.

1. Introduction

The human microbiome is the wide community of microorganisms that live in and on the human body. It consists of more than 100 trillion cells [1, 2] and contains 27 times more genes than the human genome [3–5]. The microbiome plays an important role in regulating metabolism, immune function, and behavior in humans [6].

The microbiota is represented by the community of microorganisms present on a certain body site, in particular the gastrointestinal tract (also called gut microbiota), the oral cavity, the skin, the lungs, and the genitourinary tract [2].

Until recently, the intrauterine environment was considered to be sterile except in the case of chorioamnionitis related to bacterial infections and usually associated with adverse pregnancy outcomes including preterm birth [7]. However, it is now clear that the placenta has its own “healthy” microbiota which is not necessarily associated with infections. Therefore, a specific microbiota characterizes also the placenta and the amniotic fluid [8], and it is subject to modifications with the progression of the pregnancy [9].

Gestational diabetes mellitus (GDM) is an increasing public health concern that affects approximately 5-20% of pregnancies, and its prevalence is progressively rising [10, 11]. It has been defined as any glucose intolerance with the first onset or recognition during pregnancy [12] and is associated with many adverse maternal and neonatal outcomes, such as preeclampsia, cesarean delivery, macrosomia, shoulder dystocia, and neonatal hypoglycemia [13, 14].

The role of intestinal microbiota in modulating insulin resistance and the body inflammatory response is well known [15, 16]. Therefore, the potential impact of specific interventions on the gut bacteria composition and function is of considerable interest when seeking the optimal strategy to prevent and treat GDM.

The aim of the present work is to review the role of the microbiome during pregnancy, its physiological modifications among trimesters, and its pathological changes when
pregnancy is complicated by gestational diabetes. A brief excursion on the molecular approaches to study the gut microbiome will be presented as well. In addition to this, a review of the mechanisms implicated in the correlation between microbiota alterations, adverse pregnancy outcomes, and neonatal long-term outcome will be performed.

2. Gut Microbiota

Modifications during Pregnancy

With the term “gut microbiota,” we refer to the microorganisms that colonize the gastrointestinal tract [17]. By now, we know that all these microorganisms, which are more than 100 trillion [18] classified in over 35,000 bacterial species [19], have a symbiotic exchange with the human host through the performance of multiple functions [20]: they are involved in nutrients, xenobiotic and drug metabolisms, antimicrobial protection, immunomodulation, integrity of the gut barrier, and structure of the gastrointestinal tract.

The gut microbiota is composed by several types of microorganisms, including bacteria and viruses. Bacteria are classified in phyla, classes, orders, families, genera, and species [21]. The dominant phyla are Firmicutes and Bacteroides, which represent 90% of the microbiota, followed by Actinobacteria, Proteobacteria, Fusobacteria, and Verrucomicrobia [22]. For each phylum, there are predominant genera and species, for example, Firmicutes phyla are represented by Clostridium genera for 95% of its composition but includes also other important genera like Lactobacillus, Bacillus, and Ruminococcus. The composition of the gut microbiota changes between individuals and within the same individual in relation to different factors: gestational age at birth, mode of delivery, age, diet, antibiotics, use of probiotics, body mass index (BMI), and exercise are some of the more studied elements that can influence the human gut microbiota composition. Another factor that can influence the microbiota composition is represented by pregnancy, which is characterized by profound hormonal and metabolic changes [21].

2.1. Changes of Gut Microbiota throughout Different Trimesters of Gestation. During normal pregnancies, the composition of the gut microbiota changes through the course of gestation: during the first trimester, it resembles that of a healthy nonpregnant individual [9, 23, 24], then it changes gradually, and by the third trimester, it is like the microbiota of people affected by metabolic syndrome, with the capacity to induce it if transplanted in germ-free mice [9]. In particular, the main change is represented by a reduction in α-diversity (which is the complexity of species diversity in the sample) and an increase in β-diversity (which is between-subject diversity) [25]. At the phylum level, there is an increase in Actinobacteria and Proteobacteria and a decline in butyrate-producing bacteria. Butyrate is an important short-chain fatty acid (SCFA) that can serve as a second messenger as well as a source of energy. These changes might be linked with the maternal metabolic profile, consisting of a decline in insulin sensitivity and an increase in nutrient absorption that are necessary to support a healthy pregnancy [26].

More recent studies have focalized on differences between nonpregnant and pregnant individuals at a genera and species levels, with results that are not always concordant. The genera Blautia and Collinsella have been shown to increase not only in normal pregnancy [27, 28] but also in pregnancy complicated by GDM [29]; its reduction has been associated with digestive diseases that are common in pregnancy, such as vomit and constipation, and also in disease that is more rare like acute fatty liver; these diseases have also been associated with an increase in the presence of Paenibacillus, Acinetobacter, and Enterococci [25], while in normal pregnancy, there is a reduction in Acinetobacter [27].

Recently, it has been shown that there is a change in the gut microbiota composition from first trimester to second trimester: in particular, there is an increase in Firmicutes/Bacteroides ratio, Blautia, Rothia, and Bilophila and a decrease in Bacteroides and Parabacteroides [27] (Figure 1).

Another genera that increases during pregnancy is represented by Bifidobacterium with a demonstrated causal role of progesterone in this variation as shown by using murine models with progesterone implanted subcutaneously [28]. Bifidobacterium abundance has been shown to be directly correlated with high-fat diet before and during pregnancy, just like Akkermansia [30], suggesting a possible role of pre-pregnancy diet on the type of microbial changes that occur during pregnancy, even if a previous study had shown an inverse correlation between gestational weight gain and reduced abundance of Bifidobacterium and Akkermansia [31].

Further studies are needed to elucidate the differences between the gut composition of nonpregnant individuals and healthy pregnancies. In consideration of the role played by the gut microbiota in different metabolic processes, research in this field of interest could help understanding the physiology of pregnancy microbiome modifications, and consequently, it could allow developing a strategy of interventions and prevention in high-risk pregnancies.

3. Gut Microbiota in Pregnancy: Molecular Approaches

Until recently, information about the microbes inhabiting the human body was obtained via conventional culture-based microbiology techniques, where fluid or epithelial swabs from a given body site were placed in culture media, and the organisms that grow were phenotypically and genetically characterized [32]. Nowadays, Real-Time-q Polymerase Chain Reaction (RT-qPCR), shotgun sequencing of 16S rRNA/rDNA gene sequence, and fluorescent in situ hybridization coupled with flow cytometry are most widely used to characterize the gut microbiome in human and animal models [15].

Animal models have advanced our understanding of the gut microbiome and its relationship to fetal programming. A murine model of parental high-fat diet consumption found that offspring of Western diet breeders had a significantly
Several studies have shown some differences in microbial composition between healthy pregnancy and pregnancy complicated by GDM, even if not all studies are concordant. It has been shown that GDM patients have a higher *Firmicutes*/*Bacteroidetes* ratio when compared with healthy pregnancy patients [23]. The same study found an abundance of *Akkermansia* in the control patients and increased levels of *Lachnospiraceae*, *Phascolarctobacterium*, and *Christensenellaceae* in women with GDM, but no differences at a genera level between the two groups of patients [23]. Some differences were found in the composition of gut microbiota during the third trimester of pregnancy, with the identification of phylum *Actinobacteria* as biomarkers of GDM; in the same study, the genera *Collinsella*, *Rothia*, *Actinomyces*, *Desulfovibrio*, *Leuconostoc*, *Granulicatella*, and *Mogibacterium* were biomarkers of GDM, while the genera *Marvinbryantia*, *Acetivibrio*, and *Anaeroprobacter* were markers of normal glucose regulation [35]. Another small study found that in the third trimester of women with GDM, there is a higher relative abundance of *Bacteroides coccaceae*, *Bacteroides massilensis*, and *Bacteroides thetaiotaomicron* and a reduction of *Bacteroides vulgatus*, *Eubacterium eligens*, *Lactobacillus rogosae*, and *Prevotella copri* [36]. Differences between gut microbiota in healthy pregnancy compared to pregnancy complicated with GDM are shown in Figure 2.

More recently, several studies have focused on the identification of differences in abundance and composition of the gut microbiota in the first half of pregnancy that correlate to GDM, diagnosed with the standard oral glucose tolerance test at 24-28 weeks of gestation, aimed at discovering an early biomarker for the diagnosis and treatment of gestational diabetes [27, 37–40]. During the first and second trimesters, a decreased relative abundance of *Coprococcus* and *Streptococcus* has been found, which are, respectively, a butyrate-producing bacterium and a lactate-producing bacterium. The same study also showed a positive association between GDM and *Megasphaera* and *Eggertella* [27]. Another study showed, other than a reduced alpha-diversity in patients that will develop GDM, that the genera *Bacteroides*, *Dialister*, and *Campylobacter* were taxonomic biomarkers of GDM, while the genera *Gemminer* and *Bifidobacterium* were markers of normal glucose levels during pregnancy [37]. In contrast with the result of this study, a change in GDM patients from the second to the third trimester has been reported, represented by a higher alpha-diversity, an increment in the colonization of *Firmicutes*, and a reduction in the presence of *Bacteroidetes* and *Actinobacteria* [38]. The increase of relative abundance of *Ruminococaceae* in the early pregnancy has also been associated with the subsequent development of GDM [39]. In a recent metagenomics study, an association between *Parabacteroides distasonis* and *Klebsiella variicola* in GDM in comparison to healthy pregnancies has been shown [40]. Further studies are needed to understand if interventions on gut microbiota composition in the first half of pregnancy in women with an abundance of microorganisms as markers of carbohydrate metabolism. The genera *Blautia* and *Eubacterium hallii* group was positively correlated to fasting blood glucose while the relative abundance of *Faecalibacterium* was negatively correlated to it [38, 41]; the authors suggested the possibility of using these as markers of GDM that is not controlled by diet.
High blood glucose values corresponded to low intestinal *Faecalibacterium/Fusobacterium* ratios, with the correlation highly significant between the bacterial rations and two-hour blood glucose levels, representing the regulatory and recovery capability after sugar intake [42].

Ketonuria, which is an indirect marker of glucose metabolism, has been shown to be associated with a relative abundance of *Roseburia* and also with *Faecalibacterium* and *Dialister* in overweight and obese women at 16 weeks of gestation [43], even if previous studies showed a decrease in *Roseburia intestinalis* and *Faecalibacterium prausnitzii* in patients with type 2 diabetes [44, 45].

Insulin, c-peptide, and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) have been positively associated with the genus *Collinsella* in early pregnancy of obese and overweight women [26]; the same study has noted a positive correlation between the genus *Coprococcus* and the levels of GIP (Gastric Inhibitory Peptide), an incretin that acts by stimulating insulin secretion.

HbA1c levels have been found to be correlated with *Bacteroides* and *Prevotella* [38].

It would be interesting to discover if the use of these biomarkers in the clinical practice may help improve the management of patients with GDM by recognizing patients that are not well controlled with therapy and may need further treatments.

There are some contrasts in the results of some studies, like a recent one [46] that showed no correlation between specific microbial species and GDM in obese and overweight women. The authors linked this result to the use of a more accurate approach, even if the same authors admit that other studies, using the same technique, have found a correlation between GDM and gut microbiota composition [41, 47].

A study that compared the gut microbiome composition between women with a history of GDM and nondiabetic women found no differences after five years from delivery, suggesting that there is no causal role of microbiome composition in GDM appearance [48]; however, another study evidenced a different composition in GDM after eight months from delivery compared to healthy patients, with the genera *Collinsella* and *Olsenella* found to be biomarkers of previous GDM [35].

Further studies are needed to better understand if the differences in gut microbiota composition continue after the term of pregnancies, playing a role in the development of GDM in subsequent pregnancies and if interventions on its composition in the interpregnancies interval may help prevent the onset of GDM.

### 5. Microbiota Alterations in GDM and Adverse Pregnancy Outcome

Over the course of a normal pregnancy, women undergo several physiological changes, including an increase in insulin resistance (IR). In order to compensate for this physiological resistance, insulin secretion increases gradually during gestation [49]. However, some pregnant women have a limited capacity to increase insulin production and, consequently, develop GDM [50]. Dysbiosis, an altered microbiota composition, has been hypothesized to play a key role in the pathogenesis of many acute and chronic conditions, including metabolic diseases, such as obesity, insulin resistance, and both type 1 and type 2 diabetes mellitus (T2DM) [51, 52].

The composition of the microbe changes during pregnancy. It has recently been proposed that intestinal microflora and their metabolic activities (intestinal dysbiosis) may play a critical role in body weight control, energy homeostasis, fermentation, and absorption of nondigestible carbohydrate and also in the development of IR; therefore, it may also participate in the pathogenesis of several metabolic disorders, such as obesity, diabetes mellitus, and GDM [50, 53].

In addition to the gut microbiome, the composition of the microbial community in other body sites seems to also be involved in systemic health [54–56]. The oral microbiome seems to play an important role in obesity and diabetes, through the release of inflammatory mediators that may increase the IR, suggesting a link between pathogenic periodontal bacteria (such as *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*) with glycemic control and risk of diabetes [54].
During pregnancy, there is a change in the structure of the vaginal bacterial community, leading to the production of metabolites such as lactic acid that helps to maintain low pH, which contribute to increasing the presence and stabilization of Lactobacillus in the vaginal microbiome. New data concerning the relationship between the vaginal microbiome and metabolic diseases, such as GDM, have been reported [57]. An increase of inflammatory cytokine expression has been shown in GDM, as well as an increase in the abundance of potential pathogenic bacteria, characterizing a dysbiotic profile of the vaginal microbiome [23, 57].

Currently, the etiology is unknown for some of the most important obstetric conditions, such as preeclampsia, premature preterm rupture of membranes, premature labor, preterm delivery, intrauterine growth restriction, gestational diabetes, abruptio placentae, late abortions, stillbirth, hyperemesis gravidarum, and gestational trophoblastic disease, although a microbial role has been implicated in all these conditions. In a recent publication, Romero coined the term “The great obstetrical syndromes” [58] referring to syndromes characterized by multiple etiologies, long preclinical stage, frequent fetal involvement, often adaptive clinical manifestations, and predisposing genetic interactions. Diagnosis and treatment for any of these conditions is challenging, although changes in the microbiota were suggested to play a role [59].

5.1. Cardiometabolic Adverse Outcome. There is mounting evidence supporting the role of the gut microbiome in cardiometabolic diseases in pregnancies [60, 61], and the imbalance in the gut microbiome is nowadays considered an important contribution to the development of GDM [61, 62] being already demonstrated that differences in gut microbiome composition, and its related metabolic activities, distinguish lean versus obese individuals and those with type 2 diabetes mellitus versus those without. Moreover, the finding that a different microbial pattern precedes the onset of GDM leads to the hypothesis that microbiota alterations might have a role in the pathogenesis of GDM [9, 39].

More difficult is the topic over the relationship between the composition of the microbiome in pregnancies complicated by GDM and adverse obstetrical outcomes.

5.2. Preterm Birth. Actually, the proof of a link between alteration of the microbiome in pregnancy and adverse obstetrical outcomes is various: a review of the literature [63] and a meta-analysis of 22 studies including 12,047 pregnant women showed that women with periodontitis had an increased risk of preterm delivery (PTD) and of delivering a low-birth-weight infant [64].

5.3. Gestational Hypertension, Preeclampsia, and Instrumental Delivery. A dysbiotic microbiome is implicated in the diffusion of gut bacterial endotoxin into systemic circulation, inducing a low-grade inflammatory response, which is a common feature of cardiometabolic diseases and that in turn raises the risk of maternal complications of pregnancies. Combined with insulin resistance, chronic subclinical inflammation characterizes the hallmark pathway to the development of both gestational diabetes and gestational hypertension [65]. The maternal oral, vaginal, and gut microbiome influence the risk of pregnancy outcomes and have profound impacts upon the health of the neonate and infant, potentially affecting the possibility that patients affected by GDM—given the microbiome imbalance—can be super exposed to preterm birth, preeclampsia, and excessive gestational weight gain.

The alteration of the microbiome associated with GDM may contribute to the elevated risk of pregnancy complications, including preeclampsia and instrumental or operative delivery for the mother. Fetal complications include macrosomia (birthweight greater than 4500 g), polyhydramnios, preterm birth, shoulder dystocia, and neonatal complications of admission to high-level care, respiratory distress, hypoglycemia, and jaundice. Both women with GDM and their infants are also at increased risk of diabetes mellitus and metabolic dysfunction later in life [66, 67], and this risk can be connected to the favorable outcome of subsequent pregnancies.

Although incompletely elucidated, there are a number of modifiable factors that shape the composition of the maternal microbiome, including maternal diet, prepregnancy weight and gestational weight gain, and hygiene practices. The maternal microbiome and perinatal factors establish the fetal and infant microbiome.

Indeed, treatment of GDM improves pregnancy outcomes with significant reductions in the rate of serious perinatal outcomes including macrosomia, shoulder dystocia, and cesarean delivery [68, 69]. Primary prevention of GDM rather than treatment would however be ideal in preventing both the economic and health costs associated with GDM.

As a strategy for reducing the risk of adverse pregnancy outcomes that negatively impact neonatal and infant health, practitioners should evaluate women’s attainment of a healthy maternal microbiome before and during pregnancy (via preconception and prenatal care) through the promotion of a healthy diet, achievement of a healthy weight status and weight gain during pregnancy, and oral hygiene (such as regular brushing, flossing, and dental care). In the perinatal period, the key target for promoting a healthy infant microbiome includes the promotion of breastfeeding and kangaroo care along with the judicious use and appropriate selection of antibiotics.

There is a need for research to further elucidate maternal microbiome patterns that protect against and elevate the risk for adverse pregnancy outcomes that impact neonatal and infant health and, thereafter, to identify modifiable factors that influence the composition of the maternal and infant microbiome to support the targeting of health strategies to improve pregnancy outcomes and infant health.

6. Neonatal Microbiota in Pregnanacies Complicated by GDM and Neonatal Long-Term Outcome

It is well known that the maternal environment affects the offspring health. The newborn gut microbiota is strongly influenced by maternal health and pregnancy conditions.
and participates in the development programming of the newborns [70–72]. Early disruption of the infant microbiota has been associated with many inflammatory, immune-mediated, allergic, and dysmetabolic diseases in later life [70–73].

GDM was found to be associated with specific changes in the gut microbiota composition [23, 35, 38, 40, 42]. The altered microbiome may have a crucial role in the underlying metabolic dysregulation that underpins the pathogenesis of gestational hyperglycemia, as well as the consequence of the increased adiposity frequently coexisting in GDM patients [74, 75].

6.1. Neonatal Microbiota. A possible vertical mother-to-child transmission of maternal gut bacteria has already been reported, even if, to date, certainty about the way of intrauterine microbial acquisition is lacking [76–78]. Besides breastfeeding and vaginal microbiota, placenta and amniotic fluid have also been reported to be a vehicle for this transmission [9].

Human and animal studies investigating possible causal linkage of disease programming suggest that gut microbiota dysbiosis negatively affects metabolic health triggering cardiometabolic disease onset later in life [79]. In alignment with the “developmental origin of health and disease” hypothesis, increasing evidence supports that exposure to prenatal metabolic disorders during fetal growth may contribute to health outcomes in the offspring [80].

Among full-term infants, gut microbiota consists primarily of anaerobic organisms. The “normal” infant gut microbiota develops by the colonization of facultative anaerobic organisms, later developing obligate anaerobes, including *Bifidobacterium*, *Bacteroides*, and *Clostridium* [81]. These anaerobes are associated with producing polysaccharides that mediate microbiota colonization, immune modulation, and host-gut cross-talk [70]. For example, *Clostridium* in the infant’s gut, at high levels, is pathogenic and considered unhealthy.

6.2. Childhood Microbiota. After the age of 3 years, the microbial environment changes rapidly; compositional stability occurs to resemble an adult becoming dominated by *Firmicutes* and *Bacteroidetes* [82].

Gut microbiota is associated with metabolic and immune-inflammatory axes in the liver, muscle, and brain through host pathways. Dysbiosis, or imbalance of the infant gut microbiome, may be facilitated by early exposure to environmental factors such as bacteria and viruses, which can also alter host microbiota. This dysbiosis of microbiota has long-term effects on host metabolism, leading to metabolic changes, in particular, type 1 diabetes, autoimmune disease, and obesity [70]. In humans, it is suggested that early microbial patterns may predict excessive weight gain in offspring during childhood and later in life [70, 83] and that microbiota-related epigenetic changes during early development can affect phenotypic characteristics such as obesity later in life [83]. All these data support the hypothesis that the infant’s early exposure to maternal microbiomes through a transfer of maternal gut microbiota may alter the composition of the infant’s gut microbiome.

6.3. Long-Term Health Status. Recent research reported that GDM alters the microbiota of newborns, contributing to the current understanding of intergenerational obesity and diabetes prevalence [41]. In particular, one study observed a significant reduction in the diversity of various bacterial types in GDM newborns indicating that there might be serious dysbiosis in the gut of GDM newborns [84]. Compared with those of healthy newborns, GDM newborns could be more predisposed to develop gastrointestinal diseases and metabolic syndrome at later stages in their lives [84]. These findings are consistent with previous data showing that the gut microbiota in the GDM group was associated with a lower alpha-diversity level compared with that in the healthy groups [46] which, in turn, is associated with a higher BMI [85]. Research supports that the future health of infants may be affected as the offspring of GDM mothers is more likely to develop obesity during childhood and later in life [79], and this is information that deserves to be included in the prenatal counselling of patients affected by GDM.

Future studies are needed to improve our current knowledge in terms of infant gut microbiome and weight management interventions, important for decreasing risks for obesity and cardiometabolic disorders. Studies that connect diet, microbiota, and metabolism in mothers with GDM and their offspring remain a critical key point in obstetrics research. Further work is needed to determine specific mechanisms of compositional changes in newborns and infants over time.

Finally, efforts to identify biomarkers that detect neonatal dysbiosis are required to define appropriate diagnostic approaches and design effective early intervention strategies to optimize infancy, childhood, and adult health outcomes.

7. Clinical Implications

It is clear from the literature published in this field the crucial role of proper maternal nutrition throughout pregnancy in order to maintain a balanced microbiota colonization, which is demonstrated to positively influence intrauterine and vaginal environment, thus leading to reduced risk of both maternal and neonatal metabolic dysfunction and preterm birth.

According to this, probiotics administered during pregnancy are supposed to be helpful in preventing complications such as gestational diabetes. Several studies, investigating the possible role of probiotic use versus placebo in overweight and obese pregnant women, suggest that this can be a valid proposal of prevention strategy in order to reduce maternal and neonatal metabolic dysfunction and preterm birth.

In this scenario, the use of antibiotics during pregnancy should be extremely well weighted, considering risks and benefits of treating mothers with drugs potentially harmful for the microbiota composition.

It is demonstrated that antibiotics may alter the gut microbiota, in terms of the total number of bacteria and also its composition [88, 89]. Whether this change may improve or worsen the risk of developing GDM is yet to be demonstrated. While in nonpregnant individuals it has been shown
that antibiotic exposure may increase the risk of type 2 diabetes [90], a retrospective study on 12,551 patients found no differences in the risk of GDM between pregnant women that used antibiotics during pregnancy versus women who did not [91]. Another study found that antibiotic treatment in adolescent mice reduced Bacteroidetes [92]. In contrast to this, as it has already been discussed before, Bacteroidetes, along with Dialister and Campylobacter, is considered taxonomic biomarkers of GDM [37]. So, the real impact of antibiotics on the risk of developing GDM is far to be demonstrated.

Future research should focus on demonstrating the usefulness of “mapping” the maternal microbiome early during pregnancy as a preventive strategy to detect and treat unbalanced microbiota colonization that can be later related to adverse maternal and neonatal outcomes.

8. Conclusions

It is clear that the maternal microbiome widely influences neonatal and infant microbiome, and it has been shown that microbiome pathological alterations occurring during pregnancy can lead to adverse pregnancy outcomes that negatively affect neonatal and infant long-term health status, with a consistent socioeconomic impact as well.

Further characterization of the maternal microbiome and identification of various factors that facilitate changes in microbial profiles during preconception and in the course of pregnancy may elucidate preconception and prenatal strategies for improving pregnancy outcomes and, thereby, neonatal and infant health.

Conflicts of Interest

The authors declare no conflict of interest.

References

[1] W. B. Whitman, D. C. Coleman, and W. J. Wiebe, “Prokaryotes: the unseen majority,” Proceedings of the National Academy of Sciences, vol. 95, pp. 6578–6583, 1998.
[2] The NIH HMP Working Group, J. Peterson, S. Garges et al., “The NIH human microbiome project,” Genome Research, vol. 19, no. 12, pp. 2317–2323, 2009.
[3] S. R. Gill, M. Pop, R. T. DeBoy et al., “Metagenomic analysis of the human distal gut microbiome,” Science, vol. 312, no. 5778, pp. 1355–1359, 2006.
[4] MetaHIT Consortium, J. Qin, R. Li et al., “A human gut microbial gene catalogue established by metagenomic sequencing,” Nature, vol. 464, no. 7285, pp. 59–65, 2010.
[5] B. Zhu, X. Wang, and L. Li, “Human gut microbiome: the second genome of human body,” Protein & cell, vol. 1, pp. 718–725, 2010.
[6] M. J. Bull and N. T. Plummer, “Part 1: the human gut microbiome in health and disease,” Integrative Medicine: A Clinician’s Journal, vol. 13, no. 6, p. 17e22, 2014.
[7] E. Pelzer, L. F. Gomez-Arangio, H. L. Barrett, and M. D. Nitert, “Review: maternal health and the placental microbiome,” Placenta, vol. 54, pp. 30–37, 2017.
[8] K. Aagaard, J. Ma, K. M. Antony, R. Ganu, J. Petrosinio, and J. Versalovic, “The placenta harbors a unique microbiome,” Science Translational Medicine, vol. 6, no. 237, p. 237, 2014.
[9] O. Koren, J. K. Goodrich, T. C. Cullender et al., “Host remodeling of the gut microbiome and metabolic changes during pregnancy,” Cell, vol. 150, no. 3, pp. 470–480, 2012.
[10] D. A. Sacks, D. R. Hadden, M. Marsh et al., “Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study,” Diabetes Care, vol. 35, no. 3, pp. 526–528, 2012.
[11] Y. Zhu and C. Zhang, “Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective,” Current Diabetes Reports, vol. 16, p. 7, 2016.
[12] American Diabetes Association, “Classification and diagnosis of diabetes: standards of medical care in diabetes,” Diabetes Care, vol. 41, pp. S13–S27, 2018.
[13] HAPO Study Cooperative Research Group, “Hyperglycemia and adverse pregnancy outcomes,” New England Journal of Medicine, vol. 358, pp. 1991–2002, 2008.
[14] S. Schneider, B. Hoeft, N. Freerksen et al., “Neonatal complications and risk factors among women with gestational diabetes mellitus,” Acta obstetricia et gynecologica Scandinavica, vol. 90, pp. 231–237, 2011.
[15] J. Shendure and H. Ji, “Next-generation DNA sequencing,” Nature biotechnology, vol. 26, pp. 1135–1145, 2008.
[16] B. E. Hamilton, J. A. Martin, and S. J. Ventura, “Births: preliminary data for 2011,” National Vital Statistics Report, vol. 61, pp. 1–20, 2012.
[17] C. Kunz, S. Kunz, and S. Rudloff, “Intestinal flora,” Advances in Experimental Medicine and Biology, vol. 639, pp. 67–79, 2009.
[18] E. Thursby and N. Juge, “Introduction to the human gut microbiota,” The Biochemical Journal, vol. 474, pp. 1823–1836, 2017.
[19] D. N. Frank, A. L. St Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13780–13785, 2007.
[20] S. M. Jandhyala, R. Talukdar, C. Subramanyam, H. Vuyyuru, M. Sasikala, and D. Nageshwar Reddy, “Role of the normal gut microbiota,” World Journal of Gastroenterology, vol. 21, no. 29, pp. 8877–8803, 2015.
[21] E. Rinninella, P. Raoul, M. Cintoni et al., “What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases,” Microorganisms, vol. 7, p. 14, 2019.
[22] M. Arumugam, J. Raes, E. Pelletier et al., “Enterotypes of the human gut microbiome,” Nature, vol. 473, no. 7346, pp. 174–180, 2011.
[23] R. V. Cortez, C. R. Taddei, L. G. Sparvoli et al., “Microbiome and its relation to gestational diabetes,” Endocrine, vol. 64, no. 2, pp. 254–264, 2019.
[24] M. Nuriel-Ohayon, H. Neuman, and O. Koren, “Microbial changes during pregnancy, birth, and infancy,” Frontiers in Microbiology, vol. 7, p. 1031, 2016.
[25] M. Jin, D. Li, R. J. W. Liu, X. Xu, and Y. Li, “Changes in intestinal microflora in digestive tract diseases during pregnancy,”
M. K. V. Crusell, T. H. Hansen, T. Nielsen et al., “Connections between the gut microbiome and metabolic hormones in early pregnancy in overweight and obese women,” *Diabetes*, vol. 65, no. 8, pp. 2214–2223, 2016.

W. Zheng, Q. Xu, W. Huang et al., “Gestational diabetes mellitus is associated with reduced dynamics of gut microbiota during the first half of pregnancy,” *msystems*, vol. 5, no. 2, pp. e00109–e00120, 2020.

M. Nuriel-Ohayon, H. Neuman, O. Ziv et al., “Progesterone Increases *Bifidobacterium* Relative Abundance During Late Pregnancy,” *Cell Reports*, vol. 27, no. 3, pp. 730–736.e3, 2019.

N. di Simone, A. Santamaria Ortiz, M. Specchia et al., “Recent insights on the maternal microbiota: impact on pregnancy outcomes,” *Frontiers in Immunology*, vol. 11, article 528202, 2020.

W. Gohir, F. J. Whelan, M. G. Surette, C. Moore, J. D. Schertzer, and D. M. Sloboda, “Pregnancy-related changes in the maternal gut microbiota are dependent upon the mother’s periconceptional diet,” *Gut Microbes*, vol. 6, no. 5, pp. 310–320, 2015.

A. Santacruz, M. C. Collado, L. García-Valdés et al., “Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women,” *The British Journal of Nutrition*, vol. 104, no. 1, pp. 83–92, 2010.

J. T. Staley and A. Konopka, “Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats,” *Annual Review of Microbiology*, vol. 39, pp. 321–346, 1985.

I. A. Myles, N. M. Fontecilla, B. M. Janelins, P. J. Vithayathil, J. A. Segre, and S. K. Datta, “Parental dietary fat intake alters Offspring microbiome and immunity,” *Journal of Immunology*, vol. 191, no. 6, pp. 3200–3209, 2013.

M. Schultz, C. Göttl, R. J. Young, P. Iwen, and J. A. Vanderhoof, “Administration of oral probiotic bacteria to pregnant women causes temporary infantile colonization,” *Journal of Pediatric Gastroenterology and Nutrition*, vol. 38, no. 3, pp. 293–297, 2004.

M. K. V. Crusell, T. H. Hansen, T. Nielsen et al., “Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum,” *Microbiome*, vol. 6, no. 1, p. 89, 2018.

C. Festa, L. Drago, M. Martorelli et al., “Flash on gut microbiome in gestational diabetes: a pilot study,” *New Microbiologica*, vol. 43, no. 4, pp. 195–197, 2020.

T. Chen, Y. Zhang, Y. Zhang et al., “Relationships between gut microbiota, plasma glucose and gestational diabetes mellitus,” *Journal of diabetes investigation*, vol. 12, no. 4, pp. 641–650, 2020.

I. Ferrocino, V. Ponzo, R. Gambino et al., “Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM),” *Scientific Reports*, vol. 8, no. 1, p. 12216, 2018.

K. Mokkala, N. Houttu, T. Vahlberg, E. Munukka, T. Rönnemaa, and K. Laitinen, “Gut microbiota aberrations precede diagnosis of gestational diabetes mellitus,” *Acta Diabetologica*, vol. 54, no. 12, pp. 1147–1149, 2017.

Y. S. Kuang, J.-H. Lu, S. H. Li et al., “Connections between the human gut microbiome and gestational diabetes mellitus,” *Gigascience*, vol. 6, no. 8, pp. 1–12, 2017.

G. Ye, L. Zhang, M. Wang et al., “The gut microbiota in women suffering from gestational diabetes mellitus with the failure of glycemic control by lifestyle modification,” *Journal of Diabetes Research*, vol. 2019, Article ID 31772944, 12 pages, 2019.

J. Wang, J. Zheng, W. Shi et al., “Dysbiosis of maternal and neonatal microbiota associated with gestational diabetes mellitus,” *Gut*, vol. 67, no. 9, pp. 1614–1625, 2018.

H. Robinson, H. Barrett, G. Arango, M. I. HD, L. Callaway, and M. Dekker Nitert, “Ketonuria is associated with changes to the abundance of Roseburia in the gut microbiota of overweight and obese women at 16 weeks gestation: a cross-sectional observational study,” *Nutrients*, vol. 2019, p. 11, 2019.

F. H. Karlsson, V. Tremaroli, I. Noodaew et al., “Gut metagenome in European women with normal, impaired and diabetic glucose control,” *Nature*, vol. 498, no. 7452, pp. 99–103, 2013.

J. Qin, Y. Li, Z. Cai et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” *Nature*, vol. 490, no. 7418, pp. 55–60, 2012.

K. Mokkala, N. Paulin, N. Houttu et al., “Metagenomics analysis of gut microbiota in response to diet intervention and gestational diabetes in overweight and obese women: a randomised, double-blind, placebo-controlled clinical trial,” *Gut*, vol. 70, no. 2, pp. 309–318, 2020.

Y. Wu, P. W. Bible, S. Long et al., “Metagenomic analysis reveals gestational diabetes mellitus-related microbial regulators of glucose tolerance,” *Acta Diabetologica*, vol. 57, no. 5, pp. 569–581, 2020.

S. Hasan, V. Aho, P. Pereira et al., “Gut microbiome in gestational diabetes: a cross-sectional study of mothers and offspring 5 years postpartum,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 97, no. 1, pp. 38–46, 2018.

G. di Cianni, R. Miccoli, L. Volpe, C. Lencioni, and S. del Prato, “Intermediate metabolism in normal pregnancy and in gestational diabetes,” *Diabetes/Metabolism Research and Reviews*, vol. 19, no. 4, pp. 259–270, 2003.

D. Zhang, Y. Huang, and D. Ye, “Intestinal dysbiosis: an emerging cause of pregnancy complications?,” *Medical Hypotheses*, vol. 84, pp. 233–236, 2015.

A. S. Meijninkman, V. E. Gerdes, M. Nieuwdorp, and H. Hierrem, “Evaluating causality of gut microbiota in obesity and diabetes in humans,” *Endocrine Reviews*, vol. 39, no. 2, pp. 133–153, 2018.

A. Sirca, L. Framarin, N. Leone et al., “Altered gut microbiota in type 2 diabetes: just a coincidence?,” *Current diabetes reports*, vol. 18, no. 10, p. 98, 2018.

P. D. Cani, L. Geurts, S. Matamoros, H. Plovier, and T. Duparc, “Glucose metabolism: focus on gut microbiota, the endocannabinoid system and beyond,” *Diabetes & Metabolism*, vol. 40, no. 4, pp. 246–257, 2014.

N. Makriu, M. Ojima, Y. Kou et al., “Relationship of Porphyromonas gingivalis with glycemic level in patients with type 2 diabetes following periodontal treatment,” *Oral Microbiology and Immunology*, vol. 23, no. 4, pp. 348–351, 2008.

K. Aagaard, K. Riehle, J. Ma et al., “A Metagenomic approach to characterization of the vaginal Microbiome signature in pregnancy,” *PLoS One*, vol. 7, no. 6, article e36466, 2012.

R. Romero, S. S. Hassan, P. Gajer et al., “The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women,” *Microbiome*, vol. 2, no. 1, p. 4, 2014.
B. R. Shah, R. Retnakaran, and G. L. Booth, "Microbiome in normal and pathological pregnancies: a literature overview," *American Journal of Reproductive Immunology*, vol. 80, no. 2, article e12993, 2018.

R. Romero, "Prenatal medicine: the child is the father of the man," *Journal of Maternal-Fetal and Neonatal Medicine*, vol. 22, no. 8, pp. 636–639, 2009.

M. Wohlfert, J. Goldberg, and M. Golbus, "Two thirds of spontaneous abortion/fetal deaths after genetic midtrimester amniocentesis are the result of a pre-existing subclinical inflammatory process of the amniotic cavity," *American Journal of Obstetrics and Gynecology*, vol. 172, no. 1, p. 261, 1995.

J. Stock, "Gut microbiota: an environmental risk factor for cardiovascular disease," *Atherosclerosis*, vol. 229, no. 2, pp. 440–442, 2013.

X. Zhang, D. Shen, Z. Fang et al., "Human gut microbiota changes reveal the progression of glucose intolerance," *PLoS One*, vol. 8, no. 8, p. 0071108, 2013.

J. Shen, M. S. Obin, and L. Zhao, "The gut microbiota, obesity and insulin resistance," *Molecular Aspects of Medicine*, vol. 34, no. 1, pp. 39–58, 2013.

J. K. Baskaradoss, A. Geervarghese, and A. A. Al Dosari, "Causes of adverse pregnancy outcomes and the role of maternal periodontal status – a review of the literature," *Open Dental Journal*, vol. 6, pp. 79–84, 2012.

T. Konopka and A. Paradowska-Stolarz, "Periodontitis and risk of preterm birth and low birthweight – a meta-analysis," *Ginekologia Polska*, vol. 83, no. 6, pp. 446–453, 2012.

N. Vrachnis, P. Belitsos, S. Sifakis et al., "Role of adipokines and other inflammatory mediators in gestational diabetes melitus and previous gestational diabetes mellitus," *International Journal of Endocrinology*, vol. 2012, 12 pages, 2012.

B. R. Shah, R. Retnakaran, and G. L. Booth, "Increased risk of cardiovascular disease in young women following gestational diabetes mellitus," *Diabetes Care*, vol. 31, no. 8, pp. 1668–1669, 2008.

B. R. Vohr and C. M. Boney, "Gestational diabetes: the forerunner for the development of maternal and childhood obesity and metabolic syndrome?", *The Journal of Maternal-Fetal & Neonatal Medicine*, vol. 21, no. 3, pp. 149–157, 2008.

C. A. Crowther, J. E. Hiller, J. R. Moss, A. J. McPhee, W. S. Jeffries, and J. S. Robinson, "Effect of treatment of gestational diabetes mellitus on pregnancy outcomes," *The New England Journal of Medicine*, vol. 352, no. 24, pp. 2477–2486, 2005.

M. B. Landon, C. Y. Spong, E. C. Thom et al., "A multicenter, randomized trial of treatment for mild gestational diabetes," *The New England Journal of Medicine*, vol. 361, no. 14, pp. 1339–1348, 2009.

C. Milani, S. Duranti, F. Bottacini et al., "The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota," *Microbiology and Molecular Biology Reviews*, vol. 81, no. 4, p. e000367, 2017.

C. Y. L. Chong, F. H. Bloomfield, and J. M. O’Sullivan, "Factors affecting gastrointestinal microbiome development in neonates," *Nutrients*, vol. 10, p. 274, 2018.

K. L. Buchanan and D. V. Bohórquez, "You are what you (first) eat," *Frontiers in Human Neuroscience*, vol. 12, pp. 1–7, 2018.

W. Gohir, E. M. Ratcliffe, and D. M. Sloboeda, "Of the bugs that shape us: maternal obesity, the gut microbiome, and long-term disease risk," *Pediatric Research*, vol. 77, pp. 196–204, 2015.

M. J. Saad, A. Santos, and P. O. Prada, "Linking gut microbiota and inflammation to obesity and insulin resistance," *Physiol Int*, vol. 31, pp. 283–293, 2016.

L. Zhou and X. Xiao, "The role of gut microbiota in the effects of maternal obesity during pregnancy on offspring metabolism," *Bioscience Reports*, vol. 38, no. 2, 2018.

M. J. Gosalbes, S. Llop, Y. Valles, A. Moya, F. Ballester, and M. P. Francino, "Meconium microbiota types dominated by lactic acid or enteric bacteria are differentially associated with maternal eczema and respiratory problems in infants," *Clinical and Experimental Allergy*, vol. 43, no. 2, pp. 198–211, 2013.

P. Ferretti, E. Pasolli, A. Tett et al., "Mother-to-infant microbial transmission from different body sites shapes the developing infant gut microbiome," *Cell Host & Microbe*, vol. 24, no. 1, pp. 133–145.e5, 2018.

F. Asnicar, S. Manara, M. Zolfo et al., "Studying vertical microbial transmission from mothers to infants by strain-level metagenomic mSystems*, vol. 2, no. 1, p. e00164, 2017.

for the ISCOLE Research Group, P. Zhao, E. Liu et al., "Maternal gestational diabetes and childhood obesity at age 9–11: results of a multinational study," *Diabetologia*, vol. 59, no. 11, pp. 2339–2348, 2016.

P. Agarwal, T. S. Morriseau, S. M. Kereliuk, C. A. Doucette, B. A. Wicklow, and V. W. Dolinsky, "Maternal obesity, diabetes during pregnancy and epigenetic mechanisms that influence the developmental origins of cardiometabolic disease in the offspring," *Critical Reviews in Clinical Laboratory Sciences*, vol. 55, no. 2, pp. 71–101, 2018.

S. Arboleya, N. Salazar, G. Solis et al., "Assessment of intestinal microbiota modulation ability of *Bifidobacterium* strains in *in vitro* fecal batch cultures from preterm neonates," *Anaerobe*, vol. 19, pp. 9–16, 2013.

C. J. Hill, D. B. Lynch, K. Murphy et al., "Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET cohort," *Microbiome*, vol. 5, no. 1, p. 4, 2017.

L. Chang and J. Neu, "Early factors leading to later obesity: interactions of the microbiome, epigenome, and nutrition," *Current Problems in Pediatric and Adolescent Health Care*, vol. 45, no. 5, pp. 134–142, 2015.

M. Su, Y. Nie, R. Shao et al., "Diversified gut microbiota in newborns of mothers with gestational diabetes mellitus," *PLoS One*, vol. 13, no. 10, article e0205695, 2018.

Y. Yun, H.-N. Kim, S. E. Kim et al., "Comparative analysis of gut microbiota associated with body mass index in a large Korean cohort," *BMC Microbiology*, vol. 17, no. 1, p. 151, 2017.

H. L. Barrett, M. Dekker Nitert, L. S. Conwell, L. K. Callaway, and Cochrane Pregnancy and Childbirth Group, "Probiotics for preventing gestational diabetes," *Cochrane Database of Systematic Reviews*, vol. 2014, no. 2, article CD009951, 2014.

B. L. Taylor, G. E. Woodfall, K. E. Shedy et al., "Effect of probiotics on metabolic outcomes in pregnant women with gestational diabetes: a systematic review and meta-analysis of randomized controlled trials," *Nutrients*, vol. 9, no. 5, p. 461, 2017.

B. P. Willing, S. L. Russell, and B. B. Finlay, "Shifting the balance: antibiotic effects on host-microbiota mutualism," *Nature Reviews. Microbiology*, vol. 9, no. 4, pp. 233–243, 2011.

S. Becattini, Y. Taur, and E. G. Pamer, "Antibiotic-induced changes in the intestinal microbiota and disease," *Trends in Molecular Medicine*, vol. 22, no. 6, pp. 458–478, 2016.
[90] K. H. Mikkelsen, F. K. Knop, M. Frost, J. Hallas, and A. Pottegård, “Use of antibiotics and risk of type 2 diabetes: a population-based case-control study,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 100, no. 10, pp. 3633–3640, 2015.

[91] J. F. Mission, J. Catov, T. Deihl, M. Feghali, and C. Scifres, “Antibiotic use in pregnancy, abnormal fetal growth, and development of gestational diabetes mellitus,” *American Journal of Perinatology*, vol. 36, no. 3, pp. 243–251, 2019.

[92] L. Desbonnet, G. Clarke, A. Traplin et al., “Gut microbiota depletion from early adolescence in mice: implications for brain and behaviour,” *Brain, Behavior, and Immunity*, vol. 48, pp. 165–173, 2015.